Developer docs
API playgroundTry for free, no card

Search company profiles

Parion Sciences

Full company profile

uuid000c88n

Namestring
Parion Sciences
Legal namestring
Parion Sciences, Inc.
Websiteurl
parion.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Parion Sciences is a development-stage, privately held biopharmaceutical company founded in 1999 and headquartered in Durham, North Carolina, focused on restoring innate mucosal surface defense in pulmonary and ocular diseases. The company develops a portfolio of novel epithelial sodium channel (ENaC) inhibitors — lead asset P-1037/Idrevloride for cystic fibrosis and primary ciliary dyskinesia, P-1055 for pulmonary indications, and P-321 for dry eye disease — together with the proprietary tPAD transnasal pulmonary aerosol delivery platform and a separate mucolytic agents program. All pipeline assets are investigational; no products are approved or commercially marketed.

The scientific foundation is ENaC inhibitor technology originally licensed from the University of North Carolina at Chapel Hill, supported by 30+ issued patents and an extensive publication record associated with co-founder Dr. Richard C. Boucher. Parion operates with 11–50 employees and has secured multiple FDA and EMA regulatory designations for P-1037, including FDA Orphan Drug, Fast Track, and Rare Pediatric Disease Designations (July 2020) and EMA Orphan Drug Designation (November 2020). The company is led by President & CEO Paul Boucher and a management team with senior R&D and CMC backgrounds from GSK and Grifols.

Parion's business model is licensing- and partnership-driven rather than commercial: it generates revenue through upfront payments, development and regulatory milestones, and royalties from larger pharmaceutical partners — exemplified by the $80 million upfront from Vertex Pharmaceuticals in 2015 for ENaC inhibitors and the 2017 P-321 license to Shire (later Takeda). The company has also drawn on non-dilutive funding, including NIH SBIR grants, Cystic Fibrosis Foundation Therapeutics awards ($3 million for P-1037 Phase 2), and NIH CADET program funding. Both major licensing relationships (Vertex and Shire/Takeda) were subsequently terminated, and Parion reacquired worldwide rights to both programs, placing the company back in self-development mode with its lead PCD program now positioned for late-stage clinical advancement.

Short descriptiontext

Parion Sciences is a development-stage, privately held biopharmaceutical company developing novel epithelial sodium channel (ENaC) inhibitors and the tPAD aerosol delivery platform to treat cystic fibrosis, primary ciliary dyskinesia, and dry eye disease, sourcing revenue through licensing partnerships and non-dilutive grants rather than direct product sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epithelial sodium channel inhibitors, pulmonary disease therapeutics, cystic fibrosis drug development, biopharmaceutical pipeline licensing, mucosal defense therapies
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Respiratory Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Parion Sciences generates revenue through licensing agreements where partners pay upfront fees, development and regulatory milestones, and royalties on commercial sales. Examples include the $80M upfront payment from Vertex (2015) and undisclosed option/exercise payments from Santen and Shire/Takeda.

parion.com
2Grant Funding
TypeManaged Services
Description

Non-dilutive funding from government agencies and foundations including NIH SBIR grants, Cystic Fibrosis Foundation Therapeutics awards, and NIH CADET grants ($15.6M over 5 years).

parion.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Parion Sciences is a development-stage biopharmaceutical company that researches, develops, and seeks to commercialize therapies restoring the innate mucosal surface defense of the lung and eye. Its core offerings are clinical-stage drug candidates built around proprietary epithelial sodium channel (ENaC) inhibitor technology licensed from the University of North Carolina at Chapel Hill, including P-1037 for cystic fibrosis and primary ciliary dyskinesia, P-321 for dry eye disease, and accompanying drug delivery and mucolytic platforms. Parion monetizes these assets primarily through licensing and partnership agreements with larger pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 2 CLEAN-PCD study published in The Lancet Respiratory Medicine showed idrevloride in hypertonic saline was safe and associated with significant improvement in lung function over 28 days in people with PCD compared with hypertonic saline alone
Product overview1 text field

Parion Sciences is a development-stage biopharmaceutical company with a pipeline of drug candidates and delivery technologies focused on restoring mucosal surface defense in pulmonary and ocular diseases. The core products include ENaC inhibitors P-1037 (also known as VX-371) for pulmonary diseases like Cystic Fibrosis and Primary Ciliary Dyskinesia, and P-321 for dry eye disease. The company also developed the tPAD (Trans nasal Pulmonary Aerosol Delivery) platform technology for overnight drug delivery. Additional pipeline candidates include mucolytic agents and P-1055. The company leverages ENaC inhibition technology originally developed at UNC-Chapel Hill and has partnered with Vertex, Santen/Shire, and others for development and commercialization.

Product and service5 records
1P-1037 (ENaC Pulmonary / Idrevloride / VX-371)
CategoryDrug Candidate
Description

Novel epithelial sodium channel (ENaC) inhibitor for pulmonary diseases including cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). The compound blocks sodium absorption to maintain mucus hydration and improve airway clearance. The compound has been the subject of Phase 2 trials (CLEAN-CF, CLEAN-PCD) and has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations plus EMA Orphan Drug Designation for PCD.

2P-321 (Dry Eye Disease)
CategoryDrug Candidate
Description

Topical ophthalmic ENaC inhibitor designed to restore tear film volume on the ocular surface for the treatment of dry eye disease (DED). The candidate has been out-licensed to Shire (later Takeda) for worldwide development, with Parion retaining rights after the license was terminated in October 2019.

3tPAD (Transnasal Pulmonary Aerosol Delivery)
CategoryDrug Delivery Platform
Description

Proprietary aerosol delivery platform technology designed to administer aerosolized medications transnasally through a hands-free nasal cannula overnight during sleep. Optimized to bypass nasal passages and deposit medication in the lungs under natural breathing patterns, minimizing daytime treatment burden for chronic respiratory conditions such as cystic fibrosis. Developed in collaboration with Cambridge Consultants.

4Mucolytic Agents
CategoryDrug Candidate
Description

Novel mucolytic agents designed to specifically target mucus structure and facilitate mucus clearance from the lungs. Indicated for cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, primary ciliary dyskinesia (PCD), non-CF bronchiectasis, and respiratory viral infections. Positioned as broadly effective and well-tolerated versus existing mucolytic therapies.

5P-1055
CategoryDrug Candidate
Description

ENaC inhibitor developed for pulmonary diseases and advanced as part of Parion's collaboration with Vertex Pharmaceuticals covering P-1037 and P-1055. Pulmonary rights to the program were reacquired by Parion in January 2020 after the collaboration was terminated.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-05-01
Description

License agreement granting Shire exclusive worldwide rights to develop and commercialize P-321 for dry eye disease. Shire led development with opportunity for Parion to co-fund. Agreement was terminated in October 2019, with Parion regaining exclusive worldwide rights to P-321.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2016-01-19
Description

Collaboration to develop ENaC inhibitor (ZP-1/P-1046) to treat veterinary ocular surface diseases including keratoconjunctivitis sicca (dry eye) in animals. Ceva gained worldwide development and commercial rights to ZP-1 which completed proof-of-concept clinical trial in canine KCS. Compound was originally discovered by Parion Sciences.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-06-05
Description

Collaboration to develop ENaC inhibitors for cystic fibrosis and other pulmonary diseases. Vertex received worldwide development and commercial rights to Parion's ENaC inhibitors including P-1037 and P-1055. Parion received $80 million up-front payment with potential for additional development, regulatory milestones, and tiered royalties. The collaboration was terminated in January 2020, with Parion reacquiring pulmonary rights.

4Santen Pharmaceutical
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2014-06-12
Description

Exclusive option agreement for development and commercialization of P-321 for dry eye disease in certain Asian territories. Santen made an undisclosed option payment with rights to exercise option for responsibility of all clinical, regulatory, and commercial activity in agreed Asian territories. Parion retains rights in North America, Europe, and rest of world.

parion.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensor of proprietary ENaC inhibitor technology. Parion was founded based on technology from UNC-CH. Ongoing research collaboration through NIH CADET grants with UNC-CH for mucolytic research program ($7.7M of $15.6M total awarded to UNC-CH).

Strategic tierSecondaryTypeTechnology or Integration
Description

Product development partnership for tPAD (Transnasal Pulmonary Aerosol Delivery) platform. Cambridge Consultants worked with Parion to develop the aerosol delivery system that enables CF patients to receive saltwater treatment overnight while sleeping.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed inhaled ENaC peptide inhibitors (SPX-101) for cystic fibrosis, directly competing with Parion's P-1037 on the same target pathway and indication. Most directly comparable peer by mechanism and therapeutic focus.

TypeBroad incumbent
Description

Dominant CF franchise (Trikafta) and former Parion partner for ENaC inhibitors. Comparable as a CF-focused biopharma but operates at vastly greater scale across multiple disease areas.

3Translate Bio
TypeDirect peer
Description

Developed inhaled mRNA therapies for cystic fibrosis, sharing Parion's inhaled-pulmonary CF approach but with a different mechanism. Comparable as a clinical-stage pulmonary rare-disease developer.

TypeDirect peer
Description

Inhaled antibiotic (brensocatib) developer for non-CF bronchiectasis and other pulmonary rare diseases. Comparable as a clinical-to-commercial-stage pulmonary biopharma addressing mucus-related lung disease.

TypeDirect peer
Description

Late-stage respiratory biopharma developing ensifentrine for COPD and other mucus-driven lung diseases. Comparable as an inhaled, small-molecule pulmonology company in late-stage development.

TypeDirect peer
Description

Clinical-stage developer focused on dry eye disease and ocular surface inflammation, comparable to Parion's P-321 ophthalmology program in indication, stage, and licensing-driven business model.

TypeDirect peer
Description

Develops novel therapies for ocular surface diseases including dry eye, sharing Parion's ophthalmology indication focus. Comparable as a small clinical-stage ocular biotech.

TypeDirect peer
Description

Develops water-free ocular therapies for dry eye disease and other ocular surface conditions. Comparable in the dry-eye therapeutic area and in the small-molecule ophthalmic approach.

TypeEmerging player
Description

Clinical-stage developer of RNA therapeutics including for cystic fibrosis, sharing Parion's CF therapeutic focus with a different modality. Comparable as a smaller rare-pulmonary-disease clinical player.

TypeEmerging player
Description

Clinical-stage developer of RNA-editing therapies for CF and other rare diseases. Comparable in rare-disease focus and clinical-stage profile though employing a different therapeutic modality.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Parion Sciences

Respiratory Biopharmaceuticalsparion.com

Parion Sciences is a development-stage, privately held biopharmaceutical company developing novel epithelial sodium channel (ENaC) inhibitors and the tPAD aerosol delivery platform to treat cystic fibrosis, primary ciliary dyskinesia, and dry eye disease, sourcing revenue through licensing partnerships and non-dilutive grants rather than direct product sales.

What Parion Sciences does

Parion Sciences is a development-stage, privately held biopharmaceutical company founded in 1999 and headquartered in Durham, North Carolina, focused on restoring innate mucosal surface defense in pulmonary and ocular diseases. The company develops a portfolio of novel epithelial sodium channel (ENaC) inhibitors — lead asset P-1037/Idrevloride for cystic fibrosis and primary ciliary dyskinesia, P-1055 for pulmonary indications, and P-321 for dry eye disease — together with the proprietary tPAD transnasal pulmonary aerosol delivery platform and a separate mucolytic agents program. All pipeline assets are investigational; no products are approved or commercially marketed.

The scientific foundation is ENaC inhibitor technology originally licensed from the University of North Carolina at Chapel Hill, supported by 30+ issued patents and an extensive publication record associated with co-founder Dr. Richard C. Boucher. Parion operates with 11–50 employees and has secured multiple FDA and EMA regulatory designations for P-1037, including FDA Orphan Drug, Fast Track, and Rare Pediatric Disease Designations (July 2020) and EMA Orphan Drug Designation (November 2020). The company is led by President & CEO Paul Boucher and a management team with senior R&D and CMC backgrounds from GSK and Grifols.

Parion's business model is licensing- and partnership-driven rather than commercial: it generates revenue through upfront payments, development and regulatory milestones, and royalties from larger pharmaceutical partners — exemplified by the $80 million upfront from Vertex Pharmaceuticals in 2015 for ENaC inhibitors and the 2017 P-321 license to Shire (later Takeda). The company has also drawn on non-dilutive funding, including NIH SBIR grants, Cystic Fibrosis Foundation Therapeutics awards ($3 million for P-1037 Phase 2), and NIH CADET program funding. Both major licensing relationships (Vertex and Shire/Takeda) were subsequently terminated, and Parion reacquired worldwide rights to both programs, placing the company back in self-development mode with its lead PCD program now positioned for late-stage clinical advancement.

Parion Sciences firmographics

Firmographics
Name
Parion Sciences
Legal name
Parion Sciences, Inc.
Website
https://parion.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Parion Sciences is a development-stage, privately held biopharmaceutical company developing novel epithelial sodium channel (ENaC) inhibitors and the tPAD aerosol delivery platform to treat cystic fibrosis, primary ciliary dyskinesia, and dry eye disease, sourcing revenue through licensing partnerships and non-dilutive grants rather than direct product sales.
Ownership category
akta.pro rank

Parion Sciences industry classification

Industry
Product category
Respiratory Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Epithelial sodium channel inhibitors
  • Pulmonary disease therapeutics
  • Cystic fibrosis drug development
  • Biopharmaceutical pipeline licensing
  • Mucosal defense therapies

Where Parion Sciences is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Parion Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Parion Sciences generates revenue through licensing agreements where partners pay upfront fees, development and regulatory milestones, and royalties on commercial sales. Examples include the $80M upfront payment from Vertex (2015) and undisclosed option/exercise payments from Santen and Shire/Takeda.
  2. Grant Funding: Non-dilutive funding from government agencies and foundations including NIH SBIR grants, Cystic Fibrosis Foundation Therapeutics awards, and NIH CADET grants ($15.6M over 5 years).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Parion Sciences product offering

Product offering

Core offering

Parion Sciences is a development-stage biopharmaceutical company that researches, develops, and seeks to commercialize therapies restoring the innate mucosal surface defense of the lung and eye. Its core offerings are clinical-stage drug candidates built around proprietary epithelial sodium channel (ENaC) inhibitor technology licensed from the University of North Carolina at Chapel Hill, including P-1037 for cystic fibrosis and primary ciliary dyskinesia, P-321 for dry eye disease, and accompanying drug delivery and mucolytic platforms. Parion monetizes these assets primarily through licensing and partnership agreements with larger pharmaceutical companies.

Product overview

Parion Sciences is a development-stage biopharmaceutical company with a pipeline of drug candidates and delivery technologies focused on restoring mucosal surface defense in pulmonary and ocular diseases. The core products include ENaC inhibitors P-1037 (also known as VX-371) for pulmonary diseases like Cystic Fibrosis and Primary Ciliary Dyskinesia, and P-321 for dry eye disease. The company also developed the tPAD (Trans nasal Pulmonary Aerosol Delivery) platform technology for overnight drug delivery. Additional pipeline candidates include mucolytic agents and P-1055. The company leverages ENaC inhibition technology originally developed at UNC-Chapel Hill and has partnered with Vertex, Santen/Shire, and others for development and commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • P-1037 (ENaC Pulmonary / Idrevloride / VX-371) Novel epithelial sodium channel (ENaC) inhibitor for pulmonary diseases including cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). The compound blocks sodium absorption to maintain mucus hydration and improve airway clearance. The compound has been the subject of Phase 2 trials (CLEAN-CF, CLEAN-PCD) and has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations plus EMA Orphan Drug Designation for PCD.
  • P-321 (Dry Eye Disease) Topical ophthalmic ENaC inhibitor designed to restore tear film volume on the ocular surface for the treatment of dry eye disease (DED). The candidate has been out-licensed to Shire (later Takeda) for worldwide development, with Parion retaining rights after the license was terminated in October 2019.
  • tPAD (Transnasal Pulmonary Aerosol Delivery) Proprietary aerosol delivery platform technology designed to administer aerosolized medications transnasally through a hands-free nasal cannula overnight during sleep. Optimized to bypass nasal passages and deposit medication in the lungs under natural breathing patterns, minimizing daytime treatment burden for chronic respiratory conditions such as cystic fibrosis. Developed in collaboration with Cambridge Consultants.
  • Mucolytic Agents Novel mucolytic agents designed to specifically target mucus structure and facilitate mucus clearance from the lungs. Indicated for cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, primary ciliary dyskinesia (PCD), non-CF bronchiectasis, and respiratory viral infections. Positioned as broadly effective and well-tolerated versus existing mucolytic therapies.
  • P-1055 ENaC inhibitor developed for pulmonary diseases and advanced as part of Parion's collaboration with Vertex Pharmaceuticals covering P-1037 and P-1055. Pulmonary rights to the program were reacquired by Parion in January 2020 after the collaboration was terminated.

Quantifiable outcome

  • Phase 2 CLEAN-PCD study published in The Lancet Respiratory Medicine showed idrevloride in hypertonic saline was safe and associated with significant improvement in lung function over 28 days in people with PCD compared with hypertonic saline alone

Companies that use Parion Sciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Parion Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Parion Sciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • Shire (now Takeda)coreStrategic or Co-development Partner · 1 May 2017License agreement granting Shire exclusive worldwide rights to develop and commercialize P-321 for dry eye disease. Shire led development with opportunity for Parion to co-fund. Agreement was terminated in October 2019, with Parion regaining exclusive worldwide rights to P-321.
  • Ceva and Zoion PharmasecondaryStrategic or Co-development Partner · 19 January 2016Collaboration to develop ENaC inhibitor (ZP-1/P-1046) to treat veterinary ocular surface diseases including keratoconjunctivitis sicca (dry eye) in animals. Ceva gained worldwide development and commercial rights to ZP-1 which completed proof-of-concept clinical trial in canine KCS. Compound was originally discovered by Parion Sciences.
  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 5 June 2015Collaboration to develop ENaC inhibitors for cystic fibrosis and other pulmonary diseases. Vertex received worldwide development and commercial rights to Parion's ENaC inhibitors including P-1037 and P-1055. Parion received $80 million up-front payment with potential for additional development, regulatory milestones, and tiered royalties. The collaboration was terminated in January 2020, with Parion reacquiring pulmonary rights.
  • Santen PharmaceuticalsecondaryStrategic or Co-development Partner · 12 June 2014Exclusive option agreement for development and commercialization of P-321 for dry eye disease in certain Asian territories. Santen made an undisclosed option payment with rights to exercise option for responsibility of all clinical, regulatory, and commercial activity in agreed Asian territories. Parion retains rights in North America, Europe, and rest of world.
  • University of North Carolina, Chapel HillcoreStrategic or Co-development PartnerLicensor of proprietary ENaC inhibitor technology. Parion was founded based on technology from UNC-CH. Ongoing research collaboration through NIH CADET grants with UNC-CH for mucolytic research program ($7.7M of $15.6M total awarded to UNC-CH).
  • Cambridge ConsultantssecondaryTechnology or IntegrationProduct development partnership for tPAD (Transnasal Pulmonary Aerosol Delivery) platform. Cambridge Consultants worked with Parion to develop the aerosol delivery system that enables CF patients to receive saltwater treatment overnight while sleeping.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Parion Sciences competitors and assessment

Company assessment

Direct peers

  • Spyryx Biosciences: Developed inhaled ENaC peptide inhibitors (SPX-101) for cystic fibrosis, directly competing with Parion's P-1037 on the same target pathway and indication. Most directly comparable peer by mechanism and therapeutic focus.
  • Translate Bio: Developed inhaled mRNA therapies for cystic fibrosis, sharing Parion's inhaled-pulmonary CF approach but with a different mechanism. Comparable as a clinical-stage pulmonary rare-disease developer.
  • Insmed: Inhaled antibiotic (brensocatib) developer for non-CF bronchiectasis and other pulmonary rare diseases. Comparable as a clinical-to-commercial-stage pulmonary biopharma addressing mucus-related lung disease.
  • Verona Pharma: Late-stage respiratory biopharma developing ensifentrine for COPD and other mucus-driven lung diseases. Comparable as an inhaled, small-molecule pulmonology company in late-stage development.
  • Aldeyra Therapeutics: Clinical-stage developer focused on dry eye disease and ocular surface inflammation, comparable to Parion's P-321 ophthalmology program in indication, stage, and licensing-driven business model.
  • Kala Bio: Develops novel therapies for ocular surface diseases including dry eye, sharing Parion's ophthalmology indication focus. Comparable as a small clinical-stage ocular biotech.
  • Novaliq: Develops water-free ocular therapies for dry eye disease and other ocular surface conditions. Comparable in the dry-eye therapeutic area and in the small-molecule ophthalmic approach.

Broad incumbents

  • Vertex Pharmaceuticals: Dominant CF franchise (Trikafta) and former Parion partner for ENaC inhibitors. Comparable as a CF-focused biopharma but operates at vastly greater scale across multiple disease areas.

Emerging players

  • Arcturus Therapeutics: Clinical-stage developer of RNA therapeutics including for cystic fibrosis, sharing Parion's CF therapeutic focus with a different modality. Comparable as a smaller rare-pulmonary-disease clinical player.
  • ProQR Therapeutics: Clinical-stage developer of RNA-editing therapies for CF and other rare diseases. Comparable in rare-disease focus and clinical-stage profile though employing a different therapeutic modality.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Parion Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Parion Sciences leadership team

Management profile

Number of profiles

Profiles6 records

Parion Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Parion Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parion Sciences

What does Parion Sciences do?

Parion Sciences is a development-stage biopharmaceutical company that researches, develops, and seeks to commercialize therapies restoring the innate mucosal surface defense of the lung and eye. Its core offerings are clinical-stage drug candidates built around proprietary epithelial sodium channel (ENaC) inhibitor technology licensed from the University of North Carolina at Chapel Hill, including P-1037 for cystic fibrosis and primary ciliary dyskinesia, P-321 for dry eye disease, and accompanying drug delivery and mucolytic platforms. Parion monetizes these assets primarily through licensing and partnership agreements with larger pharmaceutical companies.

Is Parion Sciences a public or private company?

Parion Sciences is a private company. It is classified as unknown and is currently operating.

When was Parion Sciences founded?

Parion Sciences was founded in 2000. It employs 11 to 50 people.

Where is Parion Sciences based?

Parion Sciences is headquartered in Durham, United States, in the North America region.

How does Parion Sciences make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are grant Funding.

Who are Parion Sciences's main competitors?

Direct peers on record are Spyryx Biosciences, Translate Bio, Insmed, Verona Pharma, Aldeyra Therapeutics, Kala Bio and Novaliq. Vertex Pharmaceuticals is listed as a broad incumbent. Emerging players are Arcturus Therapeutics and ProQR Therapeutics.

Does Parion Sciences have an API?

No public API is recorded for Parion Sciences.

What industry is Parion Sciences in?

Parion Sciences's product category is Respiratory Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireParion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory MedicineParion Sciences published positive results of its Phase 2 CLEAN-PCD study in The Lancet Respiratory Medicine, showing idrevloride in hypertonic saline safely improved lung function over 28 days in primary ciliary dyskinesia patients. The multinational, randomized, double-blind, placebo-controlled crossover trial is the largest so far and the first with a pharmaceutical industry partner. The company plans to initiate a Phase 3 study.PR NewswireShire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage PipelineShire plc reported a 110% increase in Q1 2017 product sales to $3.4 billion, driven primarily by the inclusion of legacy Baxalta sales and strong performance across its genetic diseases and internal medicine franchises. The company also announced the acquisition of exclusive worldwide rights to the investigational dry eye disease treatment P-321 from Parion Sciences.PR NewswireShire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic IndicationsShire plc and Parion Sciences have entered into a collaborative license agreement granting Shire exclusive worldwide rights to develop and commercialize P-321, an investigational treatment for dry eye disease. The deal includes an initial $20 million upfront payment and potential milestone payments bringing the total value to up to $535 million, with Parion retaining options to co-fund development. This partnership aims to leverage Shire's ophthalmic infrastructure to advance P-321 through Phase 2 clinical trials.GlobeNewswireParion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis ConferenceParion Sciences will present an abstract on transnasal delivery of hypertonic saline to children with cystic fibrosis at the 2016 North American Cystic Fibrosis Conference in Orlando. The poster includes deposition, safety, and tolerability data from a trial of a novel transnasal device developed with Cystic Fibrosis Foundation support.GlobeNewswireParion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye DiseaseParion Sciences initiated a phase 2 clinical trial of P-321 ophthalmic solution for dry eye disease, enrolling about 60 patients over 28 days. The study compares P-321 to placebo and follows earlier phase 1/2a results presented at ARVO.GlobeNewswireParion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)Parion Sciences will present clinical data on P-321 ophthalmic solution for dry eye disease at ARVO 2016 in Seattle on May 3rd. The poster reviews a trial comparing P-321 to placebo in mild-to-moderate dry eye patients. The company has completed a phase 1/2a study and is initiating additional phase 2 studies.GlobeNewswireParion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)Parion Sciences will present clinical data on P-321 ophthalmic solution for dry eye disease at ARVO 2016 in Seattle on May 3rd. The poster reviews a trial comparing P-321 to placebo in mild-to-moderate dry eye patients. The company has completed a phase 1/2a study and is initiating additional phase 2 studies.GlobeNewswireParion Sciences Announces Upcoming Presentations of Data at the North American Cystic Fibrosis Conference Being Held October 8 through 10, 2015Parion Sciences will present three abstracts on its ENaC inhibitor P-1037 and a novel in silico CFTR corrector model at the North American Cystic Fibrosis Conference in Phoenix, October 8-10, 2015. The data includes preclinical and clinical results, and the Phase 2 CLEAN-CF trial is enrolling patients aged 12 and above.GlobeNewswireCLEAN-CF Clinical Trial Expanded to Include Pediatric Cystic Fibrosis PopulationParion Sciences expanded the CLEAN-CF trial of P-1037 to include cystic fibrosis patients aged 12-17, after previously enrolling only those 18 and above. The expansion followed a pre-specified safety review by the Data Monitoring Committee. The Phase 2 trial is supported by a Cystic Fibrosis Foundation Therapeutics award.GlobeNewswireVertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary DiseasesVertex and Parion announced a collaboration to develop ENaC inhibitors for cystic fibrosis and other pulmonary diseases. Vertex will receive worldwide development and commercial rights, and Parion will get an $80 million up-front payment with potential for additional milestones and royalties. Vertex plans a Phase 2a study adding P-1037 to lumacaftor/ivacaftor in early 2016.